Lexicon Pharmaceuticals Announced New Analysis Of Phase 3 SCORED Clinical Trial Demonstrating The Protective Effects Of Sotagliflozin In Patients With Diabetic Kidney Disease
New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to Be Presented at ASN Kidney Week 2024
Express News | Lexicon Pharmaceuticals Inc - Top-Line Data for Lx9211 Now Anticipated in Q1 2025
Express News | Lexicon Announces Completion of Screening in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain (Dpnp)
Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Lexicon Pharmaceuticals: Strategic Advancements and Growth Potential Highlighted by Exclusive Licensing Deal and Undervalued Pipeline
Strategic Partnership and Financial Incentives Drive Buy Rating for Lexicon Pharmaceuticals
Express News | Lexicon Pharmaceuticals Inc - May Get From Viatris up to $185 Mln Upon Achievement of Specified Sales Milestones Under License Deal
Express News | Viatris Inc - to Pay $25 Million Upfront for Sotagliflozin Rights
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe
Express News | Viatris Announces Exclusive Licensing Agreement With Lexicon Pharmaceuticals for Sotagliflozin in All Markets Outside of the U.S. and Europe
Press Release: Viatris Announces Exclusive Licensing Agreement With Lexicon Pharmaceuticals for Sotagliflozin in All Markets Outside of the U.S. and Europe
Piper Sandler Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $10
Lexicon Pharmaceuticals Inc (LXRX) Q2 2024 Earnings Call Highlights: Strategic Advancements ...
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
Buy Rating Affirmed for Lexicon Pharmaceuticals Based on Sotagliflozin's Market Potential and Favorable Safety Data
Beyond The Numbers: 7 Analysts Discuss Lexicon Pharmaceuticals Stock
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $10
HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $10 Price Target
Lexicon Pharmaceuticals Analyst Ratings